Categories: Clinical TrialNews

National Organization for Rare Disorders (NORD) Announces $85,000 in Grant Funding for Amyloidosis and Levy-Yeboa Syndrome

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

QUINCY, Mass., Sept. 30, 2024 /PRNewswire/ — Today, the National Organization for Rare Disorders (NORD®) announced two new requests for proposal (RFP) for grant funding related to Amyloidosis and Levy-Yeboa Syndrome (LYS). NORD’s Rare Disease Research Grant Program, established in 1989, provides seed money to qualified investigators for scientific and clinical research of diseases for which there are few other sources of funding.

The deadline for initial applications is November 25, 2024.
  • NORD, with donations from the amyloidosis community, is accepting applications for one grant of up to $45,000 US for scientific and/or clinical research studies related to amyloidosis. The deadline for applications is November 25, 2024 at 11:59 p.m. PT. Learn more and view application instructions here.
  • NORD, with fundraising by the Maxwell Family, is accepting applications for one grant of up to $40,000 US for scientific and/or clinical research studies related to Levy-Yeboa syndrome (LYS). The deadline for applications is November 25, 2024 at 11:59 p.m. PT. Learn more and view application instructions here.

Grants will be awarded to qualified researchers to initiate small scientific research studies or clinical trials, the results of which could be used to obtain funding from the NIH, FDA, or other funding agencies, or to attract a corporate sponsor. Ideally, the proposed research should have the potential to lead to the development of a new or better therapy.

To learn more or submit to the 2024 NORD Research Grants Cycle, visit the Rare Disease Research Grant Program page of the NORD website.

About the National Organization for Rare Disorders (NORD®)
With a more than 40-year history of advancing care, treatments and policy, the National Organization for Rare Disorders (NORD) is the leading and longest-standing patient advocacy group for the more than 30 million Americans living with a rare disease. An independent 501(c)(3) nonprofit, NORD is dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 340 patient organization members, is committed to improving the health and well-being of people with rare diseases by driving advances in care, research and policy. For more information, visit rarediseases.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/national-organization-for-rare-disorders-nord-announces-85-000-in-grant-funding-for-amyloidosis-and-levy-yeboa-syndrome-302262743.html

SOURCE National Organization for Rare Disorders (NORD)

Staff

Recent Posts

PathAI Showcases AI-Powered Pathology Innovations at the United States and Canadian Academy of Pathology (USCAP) 114th Annual Meeting

Company to present key research advancing digital pathology and host a networking event, H&E by…

35 minutes ago

LiveWorld Reports 2024 Financial Results

LiveWorld looks to increase its AI investmentCAMPBELL, Calif. and NEW YORK , March 25, 2025…

35 minutes ago

Shineco Announces Acquisition of Medical Device Company

The Acquisition is Expected to Create Immediate Synergies with the Company’s Existing Medical Device Business …

35 minutes ago

Emerald Isle Health & Recovery Announces New Chief Executive Officer

SUN CITY, Ariz., March 25, 2025 (GLOBE NEWSWIRE) -- Emerald Isle Health & Recovery proudly…

35 minutes ago

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

AGOURA HILLS, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the…

36 minutes ago